Eprenetapopt

DB11684InvestigationalSmall molecule

Eprenetapopt has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.

Mechanism: Pharmacologically active on Cellular tumor antigen p53
Curator reviewed
Formula / weight: C₁₀H₁₇NO₃ · 199.25 g/mol (avg)
Also known as: 1-Azabicyclo(2.2.2)octan-3-one, 2-(hydroxymethyl)-2-(methoxymethyl)- · 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one · 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one · 3-QUINUCLIDINONE, 2-(HYDROXYMETHYL)-2-(METHOXYMETHYL)- · PRIMA-1MET
Code names: APR-246

Resolves to

Compound

UNIIZ41TGB4080CAS5291-32-7ChEMBLCHEMBL3186011PubChem52918385

Structure

InChIKeyBGBNULCRKBVAKL-UHFFFAOYSA-NSMILESCOCC1(CO)N2CCC(CC2)C1=O

Targets

P04637TP53

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eprenetapopt, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account